Nedaplatin and irinotecan with concurrent thoracic radiotherapy followed by docetaxel consolidation in patients with locally advanced non-small cell lung cancer.

Abstract

OBJECTIVE:

We conducted a phase II study of nedaplatin (NP) and irinotecan (CPT) with concurrent thoracic radiotherapy (TRT) followed by docetaxel for locally advanced non-small cell lung cancer (NSCLC) to determine the safety and efficacy of the treatment. Patients with stage IIIA or IIIB NSCLC were treated with 3 cycles of chemotherapy comprising NP at 50 mg/m2 and CPT at 50 mg/m2 on days 1 and 8 every 4 weeks with concurrent TRT (2 Gy/day, total 66 Gy) followed by 3 cycles of docetaxel at 60 mg/m2 on day 1 every 3 weeks.

CONCLUSION:

Fifteen patients were registered, and 8 were able to receive the entire treatment regimen. Grade 4 neutropenia and thrombocytopenia occurred in 6 and 1 patient, respectively, receiving NP and CPT with concurrent TRT. Major non-hematological toxicities were nausea, vomiting and fatigue. Grade 3 pneumonitis and esophagitis occurred in one patient each, and 4 patients developed febrile neutropenia. Docetaxel consolidation was associated with mild toxicities. Two patients died of late pulmonary failure 3 to 4 months after treatment completion, and the study was terminated. Twelve patients responded, and the median survival time, and the 1-year and 3-year survival rates were 39.3 months, 86.7% and 60.0%, respectively. In conclusion, NP and CPT with concurrent TRT is effective for patients with locally advanced NSCLC, but frequently induces pulmonary damage.

• Authors: Fumihiro Oshita, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Kouzo Yamada, Yuko Nakayama
• Journal: Journal of experimental therapeutics & oncology (J Exp Ther Oncol) Vol. 12 Issue 1 Pg. 17-23 (May 2017) ISSN: 1359-4117 [Print] United States
• PMID: 28472560 (Publication Type: Clinical Trial, Phase II, Journal Article)

Chemical References

• Organoplatinum Compounds
• Taxoids
• Docetaxel
• Irinotecan
• nedaplatin
• Camptothecin

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Camptothecin (adverse effects, analogs & derivatives, therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, radiotherapy)
• Combined Modality Therapy (adverse effects, methods)
• Docetaxel
• Female
• Humans
• Irinotecan
• Lung Neoplasms (drug therapy, radiotherapy)
• Male
• Middle Aged
• Organoplatinum Compounds (adverse effects, therapeutic use)
• Taxoids (adverse effects, therapeutic use)